Latest Administration News

Vintage Energy revises its December 2025 quarterly report to highlight a conditional agreement to acquire Metgasco’s licence interests, while production dips amid ongoing operational efforts.

Following the sale of its main business, MPR Australia has ceased operations and is exploring options including returning capital to shareholders or acquiring a new business.

Aland Equity Group Limited has completed significant capital raisings and board restructuring while navigating a challenging quarter for its flagship Growth Fund. The company is positioning itself for expansion into property funds management.

C29 Metals is progressing drilling plans at its Samsons Tank Copper project in NSW while securing a $150,000 convertible loan from a director and exploring global acquisition opportunities to diversify its portfolio.

4DMedical has rapidly commercialised its CT – VQ™ lung imaging technology following FDA clearance, securing major partnerships and regulatory approvals that position it for significant growth in North America.

Cann Group Limited has reported its first-ever free cash flow positive quarter, following a significant debt restructuring and a $9 million capital raise. Despite a softer quarterly revenue, the company is advancing new product launches and export partnerships, positioning itself for growth.

Alterity Therapeutics has bolstered its Phase 2 data for ATH434 in Multiple System Atrophy and is advancing regulatory plans for a pivotal Phase 3 trial, supported by a robust cash position of A$49.2 million.

Stakk Limited has reported a robust Q2FY26 with record cash receipts and a fortified $15.1 million cash reserve, setting the stage for breakeven in CY26 amid strong Tier-1 client momentum.

Po Valley Energy has adopted its first-ever dividend policy and announced plans to pay a maiden dividend, signalling confidence in its cash flow and future growth prospects.

Actinogen Medical’s pivotal XanaMIA trial for Alzheimer’s disease has received a green light from its independent Data Monitoring Committee to continue, reinforcing confidence in the drug’s safety and efficacy profile.

Antares Metals reported a cash outflow in operating activities for Q2 2025 but bolstered its balance sheet with a $1 million placement, positioning itself for focused exploration in Western Australia.

HeraMED has secured pivotal US commercial agreements and achieved a key Australian regulatory milestone, positioning itself for scalable growth in digital maternity care.